Natera, Inc. (NTRA)

Market Cap	27.57B +30.2%
Revenue (ttm)	2.50B +36.6%
Net Income	-226.32M
EPS	-1.64
Shares Out	143.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,145,438
Open	190.00
Previous Close	186.36
Day's Range	188.50 - 197.53
52-Week Range	131.81 - 256.36
Beta	1.57
Analysts	Strong Buy
Price Target	260.89 (+35.5%)
Earnings Date	May 7, 2026

About NTRA

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 6,140
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA
• Website: https://www.natera.com

Financial Performance

In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.

Analyst Summary

According to 19 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $260.89, which is an increase of 35.50% from the latest price.

Price Target

$260.89

(35.50% upside)

Analyst Consensus: Strong Buy